Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LUCD 
Lucid Diagnostics Inc (LUCD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: LUCD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.71
1 Year Target Price $3.71
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.27% | Avg. Invested days 20 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 138.48M USD | Price to earnings Ratio - | 1Y Target Price 3.71 |
Price to earnings Ratio - | 1Y Target Price 3.71 | ||
Volume (30-day avg) 6 | Beta 1.25 | 52 Weeks Range 0.73 - 1.80 | Updated Date 09/16/2025 |
52 Weeks Range 0.73 - 1.80 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.95 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -978.85% |
Management Effectiveness
Return on Assets (TTM) -82.33% | Return on Equity (TTM) -463.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 155799052 | Price to Sales(TTM) 31.76 |
Enterprise Value 155799052 | Price to Sales(TTM) 31.76 | ||
Enterprise Value to Revenue 35.73 | Enterprise Value to EBITDA -0.67 | Shares Outstanding 101893000 | Shares Floating 74190517 |
Shares Outstanding 101893000 | Shares Floating 74190517 | ||
Percent Insiders 27.31 | Percent Institutions 14.92 |
Upturn AI SWOT
Lucid Diagnostics Inc
Company Overview
History and Background
Lucid Diagnostics Inc, founded in 2018, focuses on the early detection of esophageal cancer. They developed a non-endoscopic technology to detect Barrett's esophagus and esophageal adenocarcinoma.
Core Business Areas
- EsoGuardu00ae Esophageal DNA Test: Non-endoscopic diagnostic test to detect biomarkers associated with Barrett's esophagus, a precursor to esophageal cancer.
- EsoChecku00ae Esophageal Cell Collection Device: Device used to collect esophageal cells for the EsoGuardu00ae test.
- Clinical Laboratory Services: Lucid Diagnostics operates a CLIA-certified laboratory to process and analyze EsoGuardu00ae samples.
Leadership and Structure
The leadership team includes Lishan Aklog, M.D. (Chairman & CEO). The company has a typical corporate structure with departments focused on R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- EsoGuardu00ae Esophageal DNA Test: A non-endoscopic test to detect Barrett's esophagus. Market share data is not publicly available. Competitors include traditional endoscopy and biopsy procedures. Revenue is primary source of company income. Targeting population with chronic heartburn symptoms.
- EsoChecku00ae Esophageal Cell Collection Device: Device used to collect esophageal cells for the EsoGuardu00ae test. Market share data is not publicly available. Competitors include traditional methods for obtaining esophageal tissue samples. It enables the non-endoscopic collection process.
Market Dynamics
Industry Overview
The industry involves diagnostic testing for gastrointestinal disorders, particularly esophageal cancer and its precursors. There is a growing emphasis on early detection and non-invasive methods.
Positioning
Lucid Diagnostics is positioned as an innovator in non-endoscopic esophageal cancer detection. Their competitive advantage lies in the convenience and accessibility of their EsoGuardu00ae test.
Total Addressable Market (TAM)
The TAM for esophageal cancer detection is estimated to be in the billions of dollars, considering the prevalence of Barrett's esophagus and the cost of traditional diagnostic methods. Lucid Diagnostics aims to capture a significant portion of this TAM through its non-invasive approach.
Upturn SWOT Analysis
Strengths
- Innovative non-endoscopic technology
- Early mover advantage in a growing market
- Strong intellectual property portfolio
- CLIA-certified laboratory
Weaknesses
- Limited clinical data compared to established methods
- Reliance on a single product (EsoGuardu00ae)
- Need for increased awareness and adoption by physicians
- High cash burn rate
Opportunities
- Expanding clinical applications for EsoGuardu00ae
- Strategic partnerships with healthcare providers
- Increasing reimbursement coverage for EsoGuardu00ae
- International market expansion
Threats
- Competition from established endoscopic methods
- Potential for new, competing non-endoscopic technologies
- Regulatory changes affecting diagnostic testing
- Failure to achieve widespread physician adoption
Competitors and Market Share
Key Competitors
- BSX
- ENDO
Competitive Landscape
Lucid Diagnostics has an advantage in non-invasive diagnostics but competes with established endoscopic procedures and larger, more diversified medical device companies. Gaining physician acceptance is critical.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increased adoption of the EsoGuard test. Revenue growth has been strong, albeit from a low base.
Future Projections: Analyst estimates project continued revenue growth as Lucid Diagnostics expands its market reach. Profitability remains a key challenge.
Recent Initiatives: Recent initiatives include expanding the sales force, increasing marketing efforts, and conducting clinical studies to demonstrate the value of EsoGuard.
Summary
Lucid Diagnostics shows promise with its innovative non-endoscopic technology, but it's still an early-stage company with high cash burn. Revenue growth is positive, but the company faces challenges in achieving profitability and gaining widespread physician adoption. Successfully navigating reimbursement landscapes will be crucial. They must increase commercialization to be successful.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lucid Diagnostics Inc. SEC filings (10-K, 10-Q), company press releases, analyst reports, market research reports.
- https://www.luciddx.com
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated based on available information and may not be precise. Financial data is based on the most recent available filings and may change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lucid Diagnostics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-10-14 | Chairman & CEO Dr. Lishan Aklog M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 72 | Website https://www.luciddx.com |
Full time employees 72 | Website https://www.luciddx.com | ||
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.